linjc16/ctgov huggingface dataset:
Predictive Factors for the Results of Epiphysiodesis in Limb Length Discrepancy

Study Overview
=================
Brief Summary
-----------------
Several techniques exist for epiphysiodesis in limb length discrepancy with different results. Most of the time the results are disappointing for this functional surgery. The aim of this study is understanding the reasons of the failures by analyzing the different steps of the medical care. The patients will be distributed in two groups : fulfilled contract and failed contract The differences between the two groups will be analyzed.

Official Title
-----------------
Predictive Factors for the Results of Epiphysiodesis in Limb Length Discrepancy

Conditions
-----------------
Limb Length Discrepancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with limb length discrepancy who had epiphysiodesis surgery Exclusion Criteria: Missing x-rays missing data bone growth not achieved
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Fulfilled contract<br>The contract before the epiphysiodesis has been fulfilled with the wanted limb length at the final analysis | |
| Failed contract<br>The contract before the epiphysiodesis hasn't been fulfilled with the wanted limb length at the final analysis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Limb length discrepancy before surgery |  | 3 months | 
| Bones length |  | 3 months | 
| Predictive bone growth |  | 3 months | 
| Time limit between consultation and surgery |  | 3 months | 
| Screw position in physis |  | 3 months | 
| Bone age at the time of surgery |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Epiphysiodesis
Different Risk Stratification Models for Prediction of Lymph Node Involvement in Endometrial Carcinoma

Study Overview
=================
Brief Summary
-----------------
Endometrial cancer is the most common malignant disease of the female genital tract and the seventh most common cause of cancer death in women in Western countries. Histological type, grade and depth of myometrial invasion are prognostic factors in early stage disease as well as risk factors for lymph node metastasis. Systematic lymphadenectomy has recently been questioned for stage I disease based on the results from two randomized trials

Official Title
-----------------
Comparison Between Different Risk Stratification Models for Prediction of Lymph Node Involvement in Endometrial Carcinoma

Conditions
-----------------
Endometrial Cancer

Intervention / Treatment
-----------------
* Procedure: hysterectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Not virgin Not having congenital anomalies Early stage Body mass index less than 35 Exclusion Criteria: virgin advanced stage sever infection especially in the pelvis lymphadenopathy for any cause lymphadenectomy for any cause BMI more than 35 Synchronous malignancies
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| endomterial cancer<br>All patients visiting the clinic at Women Health Hospital who having endometrial carcinoma with their diagnosis based on investigations (tumor marker ) , imaging, histopathology will have surgical staging consisted of total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings | Procedure: hysterectomy<br>* total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the validity of Mayo criteria risk stratification model | risk stratification model for prediction of lymph node involvement in women with endometrial carcinoma | 3 months |
Natural History of Chronic Urticaria

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the natural history of chronic urticaria in children and to identify the predictors for chronic urticaria remission.

Detailed Description
-----------------
A Prospective cohort study of 92 children who were diagnosed with chronic urticaria to investigate the natural course of chronic urticaria and to identify predictors of disease remission.

Official Title
-----------------
The Natural History of Chronic Urticaria in Childhood: A Prospective Study

Conditions
-----------------
Chronic Urticaria

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children 4-15 years of age with the diagnosis of chronic urticaria who were attending the pediatric allergy clinic, Siriraj Hospital Mahidol University, Thailand, from March 2003 to March 2009. Exclusion Criteria: Children who had isolated physical urticaria, inability to be followed up, pregnancy, underlying diseases such as cardiovascular, hepatobiliary, and renal diseases.

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic urticaria<br>Chronic urticaria, Natural history | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of Urticaria Until Remission Since Chronic Urticaria Was Diagnosed. | Remission rates at 1, 3 and 5 years after the onset of symptoms of chronic urticaria. Description in details: Actually, this study have been started in March 2003 and finally done in March 2009, which would be totally 6 years. We eventually decided to report the rate of CU remissions only at 1, 3 and 5 years after the onset of symptoms because this would be the common interval time of CU symptoms that patients needed to know how long they should have those CU symptoms or how many of them would go away their symptoms within 1, 3 or 5 years. Another reason is that the remission rate of CU between 5 and 6 years was not significantly different, so it might not need to be reported. | 6 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic urticaria, Natural course, Remission
Surgeon Experience ReSTOR A +4 Intraocular Lens (IOL)

Study Overview
=================
Brief Summary
-----------------
To collect visual outcome data post AcrySof ReSTOR Aspheric +4 implantation from surgeons throughout the United States.

Official Title
-----------------
Surgeon Experience ReSTOR Aspheric +4 Intraocular Lens (IOL)

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Device: ReSTOR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: operable cataracts; candidate for presbyopic correcting intraocular lens (IOL) Exclusion Criteria: ocular comorbidities confounding study outcomes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ReSTOR<br>AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) | Device: ReSTOR<br>* Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Acuity | Uncorrected Visual Acuity (UCVA) and Best Spectacle Corrected Visual Acuity (BSCVA) at distance (4 meters) and near at preferred distance and measured by logMAR. LogMAR is the logarithm of the minimum angle of resolution. It is a unit of measure for visual acuity (VA). A lower logMAR value indicates better visual acuity. | 1 week to 10 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Contrast Sensitivity | Contrast sensitivity is the measurement of how faded an image may become before it is indistinguishable. Contrast sensitivity was measured in photopic, mesopic, and mesopic with glare conditions at the following spatial frequencies: 1.5, 3, 6, 12, and 18 cpd (cycles per degree). Contrast sensitivity is measured in log units. A higher value for the logarithmic units translates to better contrast sensitivity. | 1 week to 10 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ReSTOR Aspheric +4 IOL
Video Laryngoscopy in Pre-hospital Critical Care

Study Overview
=================
Brief Summary
-----------------
Difficult conditions and critically ill and injured patients may complicate endotracheal intubation in the pre-hospital setting. The incidence of complications increase when two or more endotracheal intubation attempts are needed. The aim of this study is to estimate the incidence of difficult pre-hospital endotracheal intubation after the introduction of the McGrath MAC Video laryngoscope as the primary airway device for pre-hospital endotracheal intubation. Hypothesis: • In our pre-hospital critical care teams, staffed with experienced anaesthesiologists, the rate of difficult PHETI (defined as more than one intubation attempt needed to secure a patent airway) is lower than 10 %, when using the McGrath MAC VL as primary choice in pre-hospital intubations.

Conditions
-----------------
Airway Morbidity, Airway Disease, Respiratory Insufficiency, Respiratory Failure

Intervention / Treatment
-----------------
* Device: McGrath MAC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients where the anaesthesiologists on the participating pre-hospital critical care teams attempt prehospital endotracheal intubation. Exclusion Criteria: Patients< 15 years of age

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| McGrath MAC<br>McGrath MAC is a videolaryngscope | Device: McGrath MAC<br>* McGrath MAC is a videolaryngoscope<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of difficult pre-hospital endotracheal intubation |  | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Video laryngoscope, Pre-hospital, Endotracheal intubation, Difficult endotracheal intubation, Pre hospital Critical care, McGrath MAC, Airway device
Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications

Study Overview
=================
Brief Summary
-----------------
A pilot study of mapping the peripheral plasma micro-RNA and proteomics patterns in depressive patients, treated with SSRI medications. It is an observational clinical bio-markers laboratory controlled research with no device. The research includes two groups; one for patients diagnosed of having depression, and will get a standard SSRI medication regimen. Second group is for control subjects without depression. An option for a third group is planned to include first degree relatives of the depressed patients. After giving their informed consents, subjects and patients will go through standard clinical psychiatric interview, and routine clinical lab tests. Clinical standard, specific depression and anxiety questionnaires will be held at four follow-up meetings: at start; after 2 weeks; 4 weeks; and 10 weeks. Subjects and patients will be asked to give blood samples at these points of time for the lab processing: Complete plasma proteomics and specific micro-RNA levels.

Official Title
-----------------
Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications.

Conditions
-----------------
Depression

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Depressed patients,over 18 yo Untreated with SSRI, in the last 3 months Exclusion Criteria: Bipolar patients or another major psychopathology Depressive disorder clearly due to general medical condition, or drug related BMI under 18.5 or above 40 Pregnant patients Active suicidality

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Depressed Patients<br>Patients: Group of patients that are diagnosed for having depression, and are suitable for SSRI treatment. | |
| Non-Depressed Controls<br>Controls: Volunteers that had clinical screening with no depression diagnosis. | |
| Patients Relatives<br>Patient Relatives (Optional group for later stage): First degree relatives with no depression diagnosis. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Depressive symptoms remission or response rates, under usual SSRI treatment. |  | 10 weeks of follow up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depression, Selective Serotonin Reuptake Inhibitors, MicroRNAs, Proteome
Staccato Loxapine Pulmonary Safety in Patients With Asthma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety of 2 inhaled doses of Staccato Loxapine within a day in patients with asthma.

Official Title
-----------------
Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Asthma

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Inhaled loxapine @ 0 & 10 h
* Drug: Inhaled placebo @ 2 & 10 hours


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of mild to moderate persistent asthma for at least 6 months with pre-bronchodilator FEV1 ≥60% of predicted value. Exclusion Criteria: History of COPD, or any other acute or chronic pulmonary disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Inhaled loxapine @ 0 & 10 h<br>Inhalation of 10 mg of loxapine at 0 and 10 hours | Drug: Inhaled loxapine @ 0 & 10 h<br>* 10 mg, 2 doses, 10 hours apart<br>* Other names: ADASUVE;|
| Placebo Comparator: Inhaled placebo @ 2 & 10 hours<br>Inhalation of 0 mg of loxapine (placebo) at 0 and 10 hours | Drug: Inhaled placebo @ 2 & 10 hours<br>* placebo, 2 doses, 10 hours apart<br>* Other names: ADASUVE PLACEBO;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in FEV1 from baseline by spirometry |  | at each post-treatment time point (15 min to 34 hr) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in FVC from baseline by spirometry |  | at each post-treatment time point (15 min to 34 hr) | 
| Treatment emergent adverse events |  | Post-treatment time points | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Staccato loxapine
NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler

Study Overview
=================
Brief Summary
-----------------
The aim of this non-interventional study is to ensure that patients in routine clinical practice follow given treatment instructions and to evaluate the number of reliever inhalations as well as the number of patient/days with more than 8/12 total inhalations at any day. If the number of reliever inhalations and thus the received inhaled glucocorticosteroid dose is not excessive, the safety conclusions from the clinical studies can be extrapolated to real life for better acceptance of SMART (Symbicort Maintenance and Reliever Therapy).

Official Title
-----------------
NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persistent asthma Prior Symbicort Turbuhaler maintenance and reliever therapy in a single inhaler

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
asthma, SMART, inhaled, glucocorticosteroid, reliever, maintenance, single inhaler
Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?

Study Overview
=================
Brief Summary
-----------------
Progressive multifocal leucoencephalopathy (PML) is a demyelinating disease caused by John Cunningham virus (JCV) reactivation. Numerous molecules have been overstated because there were inaccurately tested in non-rigorous clinical trial. The objective is to draw lessons from repeatedly false hopes of unconfirmed PML treatments that might contribute to prescribing ineffective drugs on claimed efficacy in case reports or small series and by failing to respect the need for clinical trial evaluation before authorizing their widespread use.

Official Title
-----------------
Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?

Conditions
-----------------
AIDS, Progressive Multifocal Leucoencephalopathy (PML)

Intervention / Treatment
-----------------
* Other: Measure of overall survival


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with AR-PML Diagnosed between January 2008 and December 2015 Followed in one of the four University Hospitals' Infectious Diseases Departments Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Measure of overall survival|Measure of overall survival among AR-PML (AIDS-related PML) patients, exposed or not to maraviroc (MVC), and immune reconstitution inflammatory syndrome (IRIS) onset.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival (OS) |  | 8 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Maraviroc, John Cunningham virus (JCV), Immune reconstitution inflammatory syndrome (IRIS), Combined antiretroviral treatment (cART), Overall survival (OS)
Effect of Inflammation on Pharmacokinetics of Posaconazole

Study Overview
=================
Brief Summary
-----------------
Posaconazole plasma concentration and inflammatory markers will be determined in all samples available from routine analysis.

Detailed Description
-----------------
A prospective observational study will be performed at the University Medical Center Groningen, the Netherlands using longitudinal data collection. The design of the study will be that patients starting on posaconazole treatment will be evaluated. After informed consent is obtained medical data will be collected from the medical chart. Posaconazole plasma concentration (trough levels) and inflammatory markers (e.g. C-reactive protein) will be determined in all samples available from routine analysis (often daily). This will result in a detailed data set capturing day to day variations in inflammation and drug concentrations.

Official Title
-----------------
Effect of Inflammation on Pharmacokinetics of Posaconazole

Conditions
-----------------
Mycoses

Intervention / Treatment
-----------------
* Drug: posaconazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 yrs receiving posaconazole Written informed consent Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| posaconazole-group<br>patients receiving posaconazole for prophylaxis or treatment of invasive fungal infection | Drug: posaconazole<br>* collection plasma samples for measuring posaconazole drug concentration<br>* Other names: noxafil;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| C Reactive Protein Levels in mg/L (CRP) on Posaconazole Concentrations in mg/L | Posaconazole drug exposure during treatment in different stages of inflammation. To determine the differences in concentrations between patients a random additive effect was used. Additionally, to correct for differences in intervals between observations a first-order autoregressive correlation was used. The Wald type III test was used to assess the influence of inflammation on posaconazole concentration. | 6 months after start of treatment |